Catalyst Financial Partners LLC Raises Holdings in Stryker Co. (NYSE:SYK)

Catalyst Financial Partners LLC lifted its stake in Stryker Co. (NYSE:SYK) by 3.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,154 shares of the medical technology company’s stock after purchasing an additional 34 shares during the quarter. Catalyst Financial Partners LLC’s holdings in Stryker were worth $346,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Farmers & Merchants Trust Co of Chambersburg PA raised its holdings in shares of Stryker by 203.3% in the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after buying an additional 61 shares during the last quarter. Rogco LP acquired a new position in shares of Stryker in the 4th quarter valued at $30,000. HBC Financial Services PLLC acquired a new position in shares of Stryker in the 4th quarter valued at $37,000. Bourgeon Capital Management LLC acquired a new stake in Stryker during the 4th quarter worth about $37,000. Finally, Venturi Wealth Management LLC grew its stake in Stryker by 97.1% during the 4th quarter. Venturi Wealth Management LLC now owns 136 shares of the medical technology company’s stock valued at $41,000 after purchasing an additional 67 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SYK has been the subject of a number of research reports. UBS Group lifted their target price on Stryker from $339.00 to $351.00 and gave the stock a “neutral” rating in a report on Wednesday, May 1st. Wells Fargo & Company increased their price objective on shares of Stryker from $364.00 to $381.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 1st. Canaccord Genuity Group raised shares of Stryker from a “hold” rating to a “buy” rating and upped their price target for the company from $315.00 to $360.00 in a report on Wednesday, January 31st. Needham & Company LLC reiterated a “hold” rating on shares of Stryker in a research note on Wednesday, May 1st. Finally, TD Cowen upped their target price on Stryker from $365.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, April 11th. Four analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $365.94.

Stryker Price Performance

Shares of NYSE SYK traded down $2.86 during trading on Wednesday, hitting $329.28. The company had a trading volume of 1,169,848 shares, compared to its average volume of 1,330,950. Stryker Co. has a fifty-two week low of $249.98 and a fifty-two week high of $361.41. The company has a quick ratio of 0.99, a current ratio of 1.71 and a debt-to-equity ratio of 0.56. The stock has a fifty day simple moving average of $346.05 and a two-hundred day simple moving average of $318.84. The firm has a market capitalization of $125.44 billion, a price-to-earnings ratio of 37.59, a price-to-earnings-growth ratio of 2.54 and a beta of 0.91.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, April 30th. The medical technology company reported $2.50 EPS for the quarter, topping the consensus estimate of $2.36 by $0.14. The company had revenue of $5.24 billion during the quarter, compared to analyst estimates of $5.10 billion. Stryker had a return on equity of 23.05% and a net margin of 16.03%. Stryker’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the business earned $2.14 EPS. On average, research analysts expect that Stryker Co. will post 11.94 earnings per share for the current year.

Insider Activity at Stryker

In related news, CAO William E. Berry, Jr. sold 7,690 shares of Stryker stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the transaction, the chief accounting officer now owns 3,675 shares in the company, valued at $1,317,414. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 5.50% of the stock is owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.